This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SYNLAB Salute del bilancio

Salute finanziaria criteri di controllo 4/6

SYNLAB ha un patrimonio netto totale di €2.4B e un debito totale di €924.8M, che porta il suo rapporto debito/patrimonio netto a 39%. Le sue attività totali e le sue passività totali sono rispettivamente €4.7B e €2.3B. L'EBIT di SYNLAB è €151.2M rendendo il suo rapporto di copertura degli interessi 1.8. Ha liquidità e investimenti a breve termine pari a €300.5M.

Informazioni chiave

39.0%

Rapporto debito/patrimonio netto

€924.83m

Debito

Indice di copertura degli interessi	1.8x
Contanti	€300.47m
Patrimonio netto	€2.37b
Totale passività	€2.34b
Totale attività	€4.71b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Dec 15

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Sep 10

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 14

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 29

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €860.3M ) di SYAB superano le sue passività a breve termine ( €693.9M ).

Passività a lungo termine: Le attività a breve termine di SYAB ( €860.3M ) non coprono le sue passività a lungo termine ( €1.6B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 26.3% ) di SYAB è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di SYAB si è ridotto da 248.8% a 39% negli ultimi 5 anni.

Copertura del debito: Il debito di SYAB è ben coperto dal flusso di cassa operativo ( 45.3% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di SYAB non sono ben coperti dall'EBIT ( 1.8 x copertura).

This company listing is no longer active

SYNLAB Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

SYNLAB AG(XTRA:SYAB) dropped from Germany SDAX (Total Return) Index

First quarter 2024 earnings released: EPS: €0.11 (vs €0.13 in 1Q 2023)

SYNLAB AG Provides Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.8% to €11.93

SYNLAB AG to Report Q3, 2024 Results on Nov 07, 2024

Third quarter 2023 earnings released: EPS: €0.59 (vs €0.31 in 3Q 2022)

Synlab Launches Revolutionary Bipolar Disorder Diagnostic Test

SYNLAB AG to Report Fiscal Year 2023 Results on Mar 25, 2024

Investor sentiment improves as stock rises 17%

Price target increased by 8.2% to €11.44

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.053 (vs €0.42 loss in 2Q 2022)

SYNLAB AG Provides Significant Support for the Largest Ever Multi-National Study on Cholesterol

Upcoming dividend of €0.33 per share at 3.3% yield

Consensus EPS estimates fall by 14%

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 31%

Consensus EPS estimates fall by 18%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 11% to €15.62

Price target decreased to €16.84

SYNLAB AG, Annual General Meeting, May 17, 2023

Price target decreased to €17.08

Investor sentiment deteriorated over the past week

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Price target decreased to €17.51

Price target decreased to €18.26

Price target decreased to €18.96

SYNLAB AG (DB:SYAB) announces an Equity Buyback for 1,860,647 shares, for €31.63 million.

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Second quarter 2022 earnings released

Consensus EPS estimates increase by 14%

SYNLAB AG Revises Earnings Guidance for the Fiscal Year 2022

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency

Investor sentiment improved over the past week

SYNLAB AG Revises Earnings Guidance for 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

SYNLAB AG (DB:SYAB) acquired Sistemas Genomicos S.L. from Ascires Biomedical Group.

Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?

Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings

SYNLAB AG (DB:SYAB) agreed to acquire Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla from Médica Sur, S.A.B. de C.V. (BMV:MEDICA B).

SYNLAB AG Provides Screenings for Pupils in North Rhine-Westphalia with the So-Called Lollipop-PCR-Tests

Synlab Introduces New PCR Pooling Test Method for Companies

SYNLAB AG has completed an IPO in the amount of €1.11875 billion.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane